Company Overview and News

108
WCS And Edmonton Mixed Sweet Discounts To WTI: Darkest Before Dawn

2018-10-16 seekingalpha - 2
Activism in Canada is largely responsible for transportation constraints such as pipeline bottlenecks, hurting the Canadian economy in ways that Canadians could never imagine.
BTE CVE CRLFF CEI TOT ENB IMO CNI ZPTAF CHAP RRENF SNZYP TDG SN TRP IMO MEG HKRCP BP VET CVE BTE ECR USEG CHPE CP USO IKM CJ GST-A GST-B GST PTOAF WCP SCAZP HUSKF AXAS PTOAD SGY VET SPE TECK HSE AREX TDGCF CP ROSEU REI AMR MEGEF IPCFF TCKRF RRX ROSE PDS PRCYF RZREF HK SPGYF PTORF

 
TOT / Total S.A. 6-K (Current Report of Foreign Issuer)

2018-10-11 sec.gov
6-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 TOT

 
TOT / Total S.A. / BlackRock Inc. - null (Passive Investment)

2018-10-10 sec.gov
fr0000120271_100818.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 4) TOTAL SA -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) B15CVJ3 -------------------------------------------------------- (SEDOL Number) September 30, 2018 -------------------------------------------------------- (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of this cover page shall
TOT

 
TOT / Total S.A. / BlackRock Inc. - null (Passive Investment)

2018-10-10 sec.gov
fr0000120271_100818.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 4) TOTAL SA -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) B15CVJ3 -------------------------------------------------------- (SEDOL Number) September 30, 2018 -------------------------------------------------------- (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of this cover page shall
TOT

6
Oil Prices Rise On Iran, Hurricane Outages

2018-10-10 oilprice
Tom majored in International Business at Amsterdam’s Higher School of Economics, he is now working as news editor for Oilprice.com.
FP E BLT XOM BHPBF COG NYTAB TOT BP BHP BBL BHP BHPLF EQNR

 
EIA Report Threatens Oil Price Rally

2018-10-05 oilprice
Tom majored in International Business at Amsterdam’s Higher School of Economics, he is now working as news editor for Oilprice.com.
FP TOT

 
TOT / Total S.A. FWP

2018-10-03 sec.gov
FWP Filed pursuant to Rule 433 Registration Statements Nos. 333-224307 and 333-224307-03
TOT

 
TOT / Total S.A. 6-K (Current Report of Foreign Issuer)

2018-10-03 sec.gov
6-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washi
TOT

1
TOT / Total S.A. 424B5 (Prospectus)

2018-10-03 sec.gov - 1
424B5 Table of Contents The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has become effective upon filing with the Securities and Exchange Commission. We are not using this prospectus supplement or the attached prospectus to offer or sell these securities or to solicit offers to buy these securities in any place where the offer is not permitted.
TOT

1
TOT / Total S.A. 424B5 (Prospectus)

2018-10-03 sec.gov - 1
424B5 Table of Contents The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has become effective upon filing with the Securities and Exchange Commission. We are not using this prospectus supplement or the attached prospectus to offer or sell these securities or to solicit offers to buy these securities in any place where the offer is not permitted.
TOT

 
TOT / Total S.A. null (Current Report of Foreign Issuer)

2018-10-01 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
TOT

53
The $100 Oil Debate

2018-09-28 oilprice
Tom majored in International Business at Amsterdam’s Higher School of Economics, he is now working as news editor for Oilprice.com.
FP RDS.B RDS.A XOM RYDBF TSLA RDSB TOT RDSA RYDAF HCLP

10
Brent Oil Breaks Its Post-Crash High

2018-09-25 oilprice
Tom majored in International Business at Amsterdam’s Higher School of Economics, he is now working as news editor for Oilprice.com.
TRP RDS.B RDS.A XOM RDSB TOT RDSA ANDV MPC SOCG DO SOCGP BP CVX SOCGM RYDBF RYDAF RIG

4
Oil Nears $80 Per Barrel

2018-09-04 oilprice
Tom majored in International Business at Amsterdam’s Higher School of Economics, he is now working as news editor for Oilprice.com.
FP APC XOM TOT MPC PBR AEUA

 
TOT / Total S.A. 6-K (Current Report of Foreign Issuer)

2018-08-31 sec.gov
6-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washi
TOT

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to TOT / Total S.A. on message board site Silicon Investor.

How Quickly Can Obama Totally Destroy the US? How Quickly Can Obama Totally Destroy the US? How Quickly Can Obama Totally Destroy the US? Total System Services, Inc. (TSS) Total System Services, Inc. (TSS) Total System Services, Inc. (TSS)
TMMI - Total Multimedia TMMI - Total Multimedia TMMI - Total Multimedia QLT PhotoTherapeutics (QLTI) QLT PhotoTherapeutics (QLTI) QLT PhotoTherapeutics (QLTI)
Layoff Totals for US Companies Layoff Totals for US Companies Layoff Totals for US Companies Sumtotal(SUMT).Could Add Up To a Nice Stock Profit!! Sumtotal(SUMT).Could Add Up To a Nice Stock Profit!! Sumtotal(SUMT).Could Add Up To a Nice Stock Profit!!
International Lottery and Totalizator Systems (ITSI) International Lottery and Totalizator Systems (ITSI) International Lottery and Totalizator Systems (ITSI) AutoTradeCenter.com (AUTC) AutoTradeCenter.com (AUTC) AutoTradeCenter.com (AUTC)
Total Entertainment Inc.(TTLN) TheOnlineCasino Opens. Total Entertainment Inc.(TTLN) TheOnlineCasino Opens. Total Entertainment Inc.(TTLN) TheOnlineCasino Opens. Nasdaq100 - Totalizator Nasdaq100 - Totalizator Nasdaq100 - Totalizator
CUSIP: 89151E109